Abbott Laboratories Aktie
115,95USD | -0,34USD | -0,29% |
WKN: 850103 / ISIN: US0028241000
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 99,34 |
Vanguard Group, Inc. (Subfiler) | 9,21 |
The Vanguard Group, Inc. | 8,99 |
State Street Corp. | 4,41 |
Capital Research & Management Co. (International Investors) | 3,78 |
Vanguard Total Stock Market ETF | 3,16 |
Capital Research & Management Co. (Global Investors) | 3,06 |
BlackRock Fund Advisors | 2,82 |
Vanguard 500 Index Fund | 2,65 |
BlackRock Institutional Trust Co. NA | 2,14 |
Geode Capital Management LLC | 2,01 |
Wellington Management Co. LLP (Wellington Breakout) | 1,44 |
Fidelity 500 Index Fund | 1,23 |
Norges Bank (13F) | 1,17 |
JPMorgan Investment Management, Inc. | 1,15 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 107 000 | 109 000 | 113 000 | 115 000 | 114 000 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,30 | 0,32 | 0,38 | 0,38 | 0,35 |
Bilanz (in Mio. USD) - Aktiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 15 667 | 20 441 | 24 239 | 25 224 | 22 670 |
Summe Anlagevermögen | 52 220 | 52 107 | 50 957 | 49 214 | 50 544 |
Summe Aktiva | 67 887 | 72 548 | 75 196 | 74 438 | 73 214 |
Bilanz (in Mio. USD) - Passiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Fremdkapital | 36 586 | 39 545 | 39 172 | 37 533 | 34 387 |
Summe Eigenkapital | 31 301 | 33 003 | 36 024 | 36 905 | 38 827 |
Summe Passiva | 67 887 | 72 548 | 75 196 | 74 438 | 73 214 |
Adresse
100 Abbott Park Road, 60064-6400 Abbott Park | |
Telefon | +1 (224) 667-6100 |
Internet | http://www.abbott.com |
Management
Alison Davies
Treasurer & Vice President |
Andrea F. Wainer
Executive VP-Rapid & Molecular Diagnostics |
Claire L. Babineaux-Fontenot
Independent Director |
Daniel Gesua Sive Salvadori
Executive Vice President-Nutritional Products |
Daniel J. Starks
Independent Director |
Darren W. McDew
Independent Director |
Gene Huang
Chief Economist & Vice President |
Hubert L. Allen
Secretary, Executive VP & General Counsel |
Jim Leffelman
Manager-Expense Reporting |
Joanne T. Beck
Global Pharmaceutical Operations |
John A. McCoy
Vice President-Finance & Controller |
John G. Stratton
Independent Director |
John M. Capek
Executive Vice President-Ventures |
Karen Wong Chayavirabood
Regional Director-Asia |
Kathryn S. Collins
Vice President-Commercial Legal Operations |
Lisa D. Earnhardt
Group President-Medical Devices & Executive VP |
Mary K. Moreland
Executive Vice President-Human Resources |
Melissa Brotz
Chief Marketing & Communications Officer |
Michael F. Roman
Independent Director |
Michael G. O'Grady
Independent Director |
Michelle A. Kumbier
Independent Director |
Nancy McKinstry
Independent Director |
Paola Gonzalez
Independent Director |
Philip P. Boudreau
Chief Financial Officer & Senior VP-Finance |
Randel William Woodgrift
Senior Vice President-Cardiac Rhythm Management |
Robert B. Ford
Chairman, President & Chief Executive Officer |
Robert J. Alpern
Independent Director |
Sally E. Blount
Independent Director |
Scott J. House
Senior VP-Regulatory & Engineering Services |
Scott Leinenweber
Senior Vice President-Licensing & Acquisitions |